
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Elevation Oncology Inc (ELEV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: ELEV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 152.81% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.71M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 3451976 | Beta 1.32 | 52 Weeks Range 0.50 - 5.83 | Updated Date 02/18/2025 |
52 Weeks Range 0.50 - 5.83 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.46% | Return on Equity (TTM) -63.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -32338731 | Price to Sales(TTM) - |
Enterprise Value -32338731 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.08 | Shares Outstanding 59119100 | Shares Floating 39359693 |
Shares Outstanding 59119100 | Shares Floating 39359693 | ||
Percent Insiders 0.27 | Percent Institutions 73.79 |
AI Summary
Elevation Oncology Inc.: A Comprehensive Overview
Company Profile:
Founded in 2017, Elevation Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of transformative therapies for patients with genomically defined cancers. The company utilizes its proprietary technology platform, ELEVON, to target and disrupt oncogenic drivers and restore tumor suppression pathways.
Core Business Areas:
Elevation Oncology focuses on developing targeted therapies for patients with specific genetic alterations in their tumors. These alterations, such as mutations in genes like TP53 and KRAS, are present in many types of cancer and are often associated with poor prognosis.
Leadership and Corporate Structure:
Leadership Team:
- Dr. Siddarth Shah, MD, PhD: President and Chief Executive Officer
- Dr. David Lawrence, MD: Chief Development Officer
- Dr. David Pass, MD: Chief Medical Officer
- Dr. David Hong, MD, PhD: Chief Scientific Officer
- Mr. Matthew Scherer: Chief Financial Officer
Board of Directors:
- Dr. Michael Burgess: Chairman
- Ms. Heather Bell: Director
- Mr. Ira Kukin: Director
- Dr. Steven Shafer: Director
- Dr. Susan Molinaro: Director
Top Products and Market Share:
Elevation Oncology is a pre-revenue company and does not yet have any products on the market. The company’s lead product candidate, ELEVON 12, is currently in Phase I/II clinical trials for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Market Dynamics:
The market for targeted cancer therapies is expected to grow significantly in the coming years. According to Global Market Insights, the global market for targeted cancer therapies was valued at $97.3 billion in 2020 and is projected to reach $194.7 billion by 2027. The increasing prevalence of cancer, rising adoption of personalized medicine, and technological advancements are driving the growth of this market.
Competitors:
- AstraZeneca (AZN): AstraZeneca is a global pharmaceutical company that develops and sells a range of targeted cancer therapies, including Tagrisso for EGFR-mutated NSCLC and Lynparza for BRCA-mutated ovarian cancer.
- Amgen (AMGN): Amgen is a biotechnology company that develops and sells a range of targeted cancer therapies, including Blincyto for acute lymphoblastic leukemia and Prolia for osteoporosis.
- Pfizer (PFE): Pfizer is a global pharmaceutical company that develops and sells a range of targeted cancer therapies, including Xalkori for ALK-positive NSCLC and Ibrance for HER2-positive breast cancer.
Recent Acquisitions (past 3 years):
Elevation Oncology has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on my analysis of Elevation Oncology’s fundamentals, I would assign the stock an AI-based rating of 7 out of 10. The company has a promising technology platform with the potential to develop transformative therapies for patients with cancer. However, the company is still in the early stages of development and faces significant risks associated with clinical development. The company’s lead product candidate, ELEVON 12, has shown early promise in clinical trials. However, it is too early to determine whether the drug will be successful in the marketplace.
Sources and Disclaimers:
The information in this overview was gathered from the following sources:
- Elevation Oncology website (https://www.elevationoncology.com/)
- SEC filings
- Market research reports
This overview is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Please note that my response is based on publicly available information as of January 2023.
Additional Information:
- Financial performance: Elevation Oncology is a pre-revenue company and does not yet have any financial statements. The company is currently funded by venture capital investors.
- Growth trajectory: Elevation Oncology is a rapidly growing company with a promising pipeline of drug candidates. The company expects to initiate Phase III clinical trials for ELEVON 12 in 2023.
- Recent product launches and strategic initiatives: Elevation Oncology announced a partnership with Bristol Myers Squibb in 2022 to develop a combination therapy for KRAS G12C-mutated NSCLC. The company also initiated a Phase II clinical trial for ELEVON 12 in combination with chemotherapy in KRAS G12C-mutated NSCLC.
- Potential challenges and opportunities: Elevation Oncology faces several potential challenges, including competition from other pharmaceutical companies, the risk of clinical trial failure, and the regulatory approval process. However, the company also has the potential to capitalize on significant opportunities, such as the growing market for targeted cancer therapies and the potential development of breakthrough therapies.
I hope this overview provides a comprehensive understanding of Elevation Oncology Inc. and its potential as an investment.
About Elevation Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-25 | CEO, President & Director Mr. Joseph J. Ferra Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://elevationoncology.com |
Full time employees 29 | Website https://elevationoncology.com |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.